Gilead and MSD to advance once-weekly HIV treatment to Phase III
Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising results from a …
Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising results from a …
Editas Medicine and Genevant Sciences will collaborate to develop gene editing therapies, employing their respective CRISPR and LNP technologies under …
On 20 October 2024, the International Osteoporosis Foundation (IOF) led global observances for World Osteoporosis Day, with a focus on …
MangoRx said it “strongly refutes” claims made by Eli Lilly that it improperly copied blockbuster weight-loss medicines for sale on …
IoT, cloud computing, data analytics, AI, real-time visibility – all phrases that once struck fear into the hearts of pharma …
Disruption is a pressing problem in the pharmaceutical world; patient health depends on the smooth and predictable movement of resources …
Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology. Avacta will gain …
The European Union's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ …
Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of …
GSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge University Hospitals …
Thermo Fisher Scientific has announced that its in vitro diagnostic test, Oncomine, has won US Food and Drug Administration (FDA) …
On October 20, at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, IL, US, …
Sanofi has entered exclusive talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of the …
Arcutis Biotherapeutics' subsidiary, Arcutis Canada, has received Health Canada's approval for ZORYVE (roflumilast) topical foam 0.3%, to treat seborrheic dermatitis …
PureTech-founded Seaport Therapeutics has raised $225m in a Series B financing round to support the development of new prodrug treatments …